- Home
- NCTY vs CRBP Comparison
NCTY vs CRBP Comparison
Compare NCTY & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- CRBP
- Stock Information
- Founded
- NCTY 1999
- CRBP 2009
- Country
- NCTY China
- CRBP United States
- Employees
- NCTY N/A
- CRBP N/A
- Industry
- NCTY Business Services
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- NCTY Consumer Discretionary
- CRBP Health Care
- Exchange
- NCTY Nasdaq
- CRBP Nasdaq
- Market Cap
- NCTY 121.2M
- CRBP 114.8M
- IPO Year
- NCTY 2004
- CRBP N/A
- Fundamental
- Price
- NCTY $10.02
- CRBP $11.62
- Analyst Decision
- NCTY
- CRBP Strong Buy
- Analyst Count
- NCTY 0
- CRBP 11
- Target Price
- NCTY N/A
- CRBP $51.90
- AVG Volume (30 Days)
- NCTY 57.4K
- CRBP 119.4K
- Earning Date
- NCTY 01-01-0001
- CRBP 11-06-2025
- Dividend Yield
- NCTY N/A
- CRBP N/A
- EPS Growth
- NCTY N/A
- CRBP N/A
- EPS
- NCTY N/A
- CRBP N/A
- Revenue
- NCTY $15,305,175.00
- CRBP N/A
- Revenue This Year
- NCTY N/A
- CRBP N/A
- Revenue Next Year
- NCTY N/A
- CRBP $220.00
- P/E Ratio
- NCTY N/A
- CRBP N/A
- Revenue Growth
- NCTY N/A
- CRBP N/A
- 52 Week Low
- NCTY $6.28
- CRBP $4.64
- 52 Week High
- NCTY $20.59
- CRBP $55.69
- Technical
- Relative Strength Index (RSI)
- NCTY 55.26
- CRBP 71.90
- Support Level
- NCTY $9.06
- CRBP $9.06
- Resistance Level
- NCTY $11.20
- CRBP $9.73
- Average True Range (ATR)
- NCTY 0.73
- CRBP 0.65
- MACD
- NCTY 0.13
- CRBP 0.08
- Stochastic Oscillator
- NCTY 55.13
- CRBP 85.93
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.